CLINICAL TRIALS PROFILE FOR ARICEPT ODT

All Clinical Trials for ARICEPT ODT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000173 ↗	Memory Impairment Study (Mild Cognitive Impairment Study)	Completed	Alzheimer's Disease Cooperative Study (ADCS)	Phase 3	1999-03-01	The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 ↗	Memory Impairment Study (Mild Cognitive Impairment Study)	Completed	National Institute on Aging (NIA)	Phase 3	1999-03-01	The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 ↗	Study of the Pathogenesis of Rett Syndrome	Completed	Johns Hopkins University	N/A	1995-01-01	OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00004807 ↗	Study of the Pathogenesis of Rett Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	1995-01-01	OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00018278 ↗	Electrophysiologic Measures of Treatment Response in Alzheimer Disease	Completed	US Department of Veterans Affairs	Phase 4	1998-10-01	The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Clinical Trial Conditions for ARICEPT ODT

Condition Name

Condition Name for ARICEPT ODT
Intervention	Trials
Alzheimer's Disease	36
Alzheimer Disease	22
Healthy	14
Dementia	10

Condition MeSH

Condition MeSH for ARICEPT ODT
Intervention	Trials
Alzheimer Disease	67
Dementia	25
Cognitive Dysfunction	19
Cognition Disorders	15

Clinical Trial Locations for ARICEPT ODT

Trials by Country

Trials by Country for ARICEPT ODT
Location	Trials
United States	341
Canada	46
Japan	28
Korea, Republic of	25
United Kingdom	23

Trials by US State

Trials by US State for ARICEPT ODT
Location	Trials
California	25
Florida	21
Texas	21
New York	18
Arizona	17

Clinical Trial Progress for ARICEPT ODT

Clinical Trial Phase

Clinical Trial Phase for ARICEPT ODT
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	32
Phase 3	21

Clinical Trial Status

Clinical Trial Status for ARICEPT ODT
Clinical Trial Phase	Trials
Completed	112
Terminated	16
Unknown status	7

Clinical Trial Sponsors for ARICEPT ODT

Sponsor Name

Sponsor Name for ARICEPT ODT
Sponsor	Trials
Pfizer	18
Eisai Inc.	15
National Institute of Mental Health (NIMH)	9

Sponsor Type

Sponsor Type for ARICEPT ODT
Sponsor	Trials
Industry	118
Other	93
NIH	25

Executive summary

Last updated: July 27, 2026

• ARICEPT ODT (donepezil hydrochloride orally disintegrating tablet) is an established, small-molecule Alzheimer’s therapy with an established generic presence in the US.
• This update covers clinical-development status, market positioning, and commercialization projections at a level that supports R&D, licensing, litigation, and investment decisions.
• No current, sufficiently verified public data were provided here to support a precise “clinical trials update” for a specific new ARICEPT ODT program (trial identifiers, sponsors, phase, enrollment, readouts, and timelines).

ARICEPT ODT (donepezil orally disintegrating tablet) clinical trials update: What studies are ongoing and what’s the latest?

Are there any current ARICEPT ODT clinical trials in Phase 2/3?

No sufficiently verifiable public trial record set was provided in the available input to confirm active Phase 2/3 ARICEPT ODT-specific studies (NCT-level granularity, sponsor, phase, endpoints, dosing, and sites).

What types of trials drive updates for an established donepezil ODT product?

For legacy branded Alzheimer’s drugs and their ODT/lifecycle forms, clinical-trials activity typically concentrates in:

• Bioequivalence (BE) and bridging studies supporting generic/or product lifecycle switches (ODT vs film-coated vs immediate-release tablets).
• Formulation performance work (disintegration time, dissolution, stability).
• Tolerability in older populations (GI tolerability, adherence endpoints).

What endpoints matter most for donepezil ODT clinical evidence?

When the goal is regulatory support or lifecycle validation, endpoints usually include:

• PK/BE: Cmax, Tmax, AUC, relative bioavailability.
• Product performance: disintegration and dissolution profiles.
• Adherence/tolerability: discontinuation rates, adverse-event burden (often GI-related).

ARICEPT ODT market analysis 2025: What is the current US and global demand outlook?

How big is the donepezil market versus Alzheimer’s total prescriptions?

ARICEPT is a long-standing therapy in Alzheimer’s disease (AD) symptomatic management. Practical market sizing depends on:

• AD patient counts and diagnosis rates.
• Penetration of cholinesterase inhibitors.
• Substitution by generics and by alternative symptomatic agents.

For an ODT-specific product, commercial volume is typically a subset of the broader donepezil/ARICEPT brand category due to:

• Generic penetration across donepezil.
• Clinician and patient preference for swallowability in dysphagia or adherence-sensitive patients.

What is the competitive landscape for donepezil formulations (tablet vs ODT)?

Competitive pressure is driven by:

• Generic donepezil immediate-release tablets (and generics of branded equivalents).
• Other formulation formats offering similar adherence benefits.
• Payer formularies that push lowest net cost options while reserving brand access for “medical necessity” or patient preference.

How does ODT positioning change payer and formulary dynamics?

OTD tends to face two market realities:

• Higher unit cost than generic tablets, requiring justification (adherence or swallowing difficulty).
• Limited “new-to-market” prescriber adoption because Alzheimer’s symptomatic therapy already has routine prescribing channels.

When does ARICEPT ODT face generic substitution risk? How does exclusivity affect commercial survival?

What patents protect ARICEPT ODT?

No patent estate details were included in the provided input. Without Orange Book listing data, patent numbers, expiration dates, and Orange Book deltas for ARICEPT ODT, a precise exclusivity assessment cannot be produced.

When does ARICEPT ODT lose exclusivity in the US?

No verified US exclusivity timeline was provided in the input.

What generic entry risks exist for donepezil ODT in 2025-2030?

Given the age of donepezil’s origin, generic substitution risk is structurally elevated for legacy formats. ODT-specific risk depends on:

• Remaining listed intellectual property for that exact dosage form and formulation.
• Any method-of-use or manufacturing protections.
• Whether generics are already marketed for ODT in key geographies.

ARICEPT ODT revenue projection 2026-2032: What growth or decline trajectory is most likely?

What drives revenue for ARICEPT ODT in an era of generics?

For legacy branded products, revenue trajectory typically depends on:

• Net price and rebate levels, not headline list price.
• Switching behavior to generic donepezil tablets.
• ODT channel retention for adherence and dysphagia populations.
• Competitive intensity from alternative cholinesterase inhibitors and memantine combinations.

Base case projection logic (directional, not contract-backed)

A defensible projection framework for an ODT legacy brand generally follows:

• Decline and plateau: branded volume erodes as prescribers and PBMs shift to lower-cost generics.
• Stabilization pockets: persistent demand for ODT among patients with swallowing difficulty.
• Market-share consolidation: if the branded ODT remains a recognized option, it can maintain a smaller but steadier slice even as total donepezil volume grows modestly with population aging.

US vs ex-US split: what usually changes outside the US?

In non-US markets, trajectory differs based on:

• Local patent enforcement histories and product launches.
• National tender pricing and reimbursement.
• Availability of equivalent ODT generics.

No verified region-specific launch and pricing data were provided, so a numeric forecast cannot be grounded to sources within this response.

What is the FDA regulatory status of ARICEPT ODT? Orange Book status and labeling considerations

What is the Orange Book status of donepezil ODT?

No Orange Book listing content was provided in the input.

What labeling content typically guides clinical uptake for donepezil ODT?

Labeling generally supports:

• Indication for Alzheimer’s dementia.
• Dosing schedule and titration.
• Adverse reactions monitoring.
• Contraindications and precautions.

Without the exact label text and current labeling version in the input, a compliant product-specific summary cannot be stated.

ARICEPT ODT vs competing Alzheimer’s drugs: How does donepezil compare on market and clinical adoption?

How does donepezil ODT compare with other cholinesterase inhibitors (rivastigmine, galantamine)

Commercial adoption is driven by:

• Formulation options (capsules, patches, ODT equivalents).
• Tolerability profiles and dosing frequency.
• Patient preference and administration feasibility.

However, a product-to-product market comparison requires verified market-share and TRx data by geography, which was not included here.

How does donepezil compare with memantine and combination approaches?

Cholinesterase inhibitors (including donepezil) are symptomatic for cognition in mild-to-moderate Alzheimer’s, while memantine targets NMDA pathways and is often used in moderate-to-severe disease. Uptake is influenced by:

• Disease stage distribution.
• Prescriber familiarity.
• Payer coverage and combination pricing.

Key takeaways

• ARICEPT ODT is a legacy donepezil formulation whose growth ceiling is typically constrained by generic competition and payer substitution.
• A precise clinical-trials update for ARICEPT ODT-specific current programs cannot be produced from the provided input because no trial registry identifiers or phase/readout details were included.
• Market projection requires verified brand TRx, net pricing, and competitive ODT availability, which were not included in the input.

FAQs

1. What is the typical role of donepezil ODT in Alzheimer’s adherence management compared with standard tablets?
2. How do PBMs usually treat cholinesterase inhibitor ODT formulations versus tablet generics?
3. Which endpoints do BE studies for ODT formulations of donepezil generally focus on?
4. What drivers explain why some patients remain on a branded ODT when generics are available?
5. How do disease-stage shifts (mild/moderate/severe) influence demand for cholinesterase inhibitors like donepezil?

References

1. (No citable sources were provided in the input.)